Purifloh Limited announced that Tuberculosis Bacteria trials commenced earlier in January at the Government General and Chest Hospital of Hyderbad. Testing protocols have been designed that initially require the determination of existing levels of TB in the Hospital environment. The initial baseline sampling and analysis exhibits a high level of airborne mould that grows rapidly when cultured, and thus supersaturated the baseline samples, impacting the ability to accurately count background TB levels. Typically, mould grows rapidly in 2-3 days, while TB grows slowly in 8-10 days in a culture medium. Accurate baseline counts are critical to the integrity of the testwork and require resolution before progressing to the efficacy trials which will incorporate the Free Radical Generator. Somnio has informed the company that there have been modifications to the testing protocols to overcome the challenge of the airborne mould and the early indications are promising. Trials continue and The company expects the issue to be resolved shortly. It is worth noting that the FRG is capable of destroying mould. Hence these trials should also demonstrate FRG's ability to significantly improve the hospital environment through the destruction of mould, in addition to the anticipated destruction of TB. The Company remains fully expectant that this testwork will produce successful results. Success would be measured by the level of reduction in airborne TB (and the associated airborne mould) and will provide the first in situ results for the FRG in an operating medical environment. This will significantly enhance the company's value proposition in air purification, whilst setting the stage for entry into the medical segment, for which further information will be released as appropriate. The company will release a detailed update on the TB testing as soon as the full results have been received and verified.